 | • レポートコード：GIR-2104Z10040 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、非ホジキンリンパ腫治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。非ホジキンリンパ腫治療薬の種類別市場規模（化学療法、標的療法）、用途別市場規模（臨床研究、治療）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・非ホジキンリンパ腫治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Bristol Myers Squibb、Celgene、Eli Lilly、F. Hoffman La-Roche、GlaxoSmithKline、Accredo Health Group、Baxter International、Bayer、Cephalon、Eisai Pharmaceuticals ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：化学療法、標的療法 ・用途別分析2016年-2026年：臨床研究、治療 ・非ホジキンリンパ腫治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・非ホジキンリンパ腫治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・非ホジキンリンパ腫治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・非ホジキンリンパ腫治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・非ホジキンリンパ腫治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Non-Hodgkin Lymphoma Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Non-Hodgkin Lymphoma Therapeutics size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Non-Hodgkin Lymphoma Therapeutics market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Non-Hodgkin Lymphoma Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Chemotherapy
Targeted Therapy
Market segment by Application, can be divided into
Clinical Research
Treatment
Market segment by players, this report covers
Bristol Myers Squibb
Celgene
Eli Lilly
F. Hoffman La-Roche
GlaxoSmithKline
Accredo Health Group
Baxter International
Bayer
Cephalon
Eisai Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Non-Hodgkin Lymphoma Therapeutics
1.2 Classification of Non-Hodgkin Lymphoma Therapeutics by Type
1.2.1 Overview: Global Non-Hodgkin Lymphoma Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Non-Hodgkin Lymphoma Therapeutics Revenue Market Share by Type in 2020
1.2.3 Chemotherapy
1.2.4 Targeted Therapy
1.3 Global Non-Hodgkin Lymphoma Therapeutics Market by Application
1.3.1 Overview: Global Non-Hodgkin Lymphoma Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Clinical Research
1.3.3 Treatment
1.4 Global Non-Hodgkin Lymphoma Therapeutics Market Size & Forecast
1.5 Global Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast by Region
1.5.1 Global Non-Hodgkin Lymphoma Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Non-Hodgkin Lymphoma Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Non-Hodgkin Lymphoma Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Non-Hodgkin Lymphoma Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Non-Hodgkin Lymphoma Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Non-Hodgkin Lymphoma Therapeutics Market Drivers
1.6.2 Non-Hodgkin Lymphoma Therapeutics Market Restraints
1.6.3 Non-Hodgkin Lymphoma Therapeutics Trends Analysis
2 Company Profiles
2.1 Bristol Myers Squibb
2.1.1 Bristol Myers Squibb Details
2.1.2 Bristol Myers Squibb Major Business
2.1.3 Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Product and Solutions
2.1.4 Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Bristol Myers Squibb Recent Developments and Future Plans
2.2 Celgene
2.2.1 Celgene Details
2.2.2 Celgene Major Business
2.2.3 Celgene Non-Hodgkin Lymphoma Therapeutics Product and Solutions
2.2.4 Celgene Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Celgene Recent Developments and Future Plans
2.3 Eli Lilly
2.3.1 Eli Lilly Details
2.3.2 Eli Lilly Major Business
2.3.3 Eli Lilly Non-Hodgkin Lymphoma Therapeutics Product and Solutions
2.3.4 Eli Lilly Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Eli Lilly Recent Developments and Future Plans
2.4 F. Hoffman La-Roche
2.4.1 F. Hoffman La-Roche Details
2.4.2 F. Hoffman La-Roche Major Business
2.4.3 F. Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Product and Solutions
2.4.4 F. Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 F. Hoffman La-Roche Recent Developments and Future Plans
2.5 GlaxoSmithKline
2.5.1 GlaxoSmithKline Details
2.5.2 GlaxoSmithKline Major Business
2.5.3 GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Product and Solutions
2.5.4 GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 GlaxoSmithKline Recent Developments and Future Plans
2.6 Accredo Health Group
2.6.1 Accredo Health Group Details
2.6.2 Accredo Health Group Major Business
2.6.3 Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Product and Solutions
2.6.4 Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Accredo Health Group Recent Developments and Future Plans
2.7 Baxter International
2.7.1 Baxter International Details
2.7.2 Baxter International Major Business
2.7.3 Baxter International Non-Hodgkin Lymphoma Therapeutics Product and Solutions
2.7.4 Baxter International Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Baxter International Recent Developments and Future Plans
2.8 Bayer
2.8.1 Bayer Details
2.8.2 Bayer Major Business
2.8.3 Bayer Non-Hodgkin Lymphoma Therapeutics Product and Solutions
2.8.4 Bayer Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Bayer Recent Developments and Future Plans
2.9 Cephalon
2.9.1 Cephalon Details
2.9.2 Cephalon Major Business
2.9.3 Cephalon Non-Hodgkin Lymphoma Therapeutics Product and Solutions
2.9.4 Cephalon Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Cephalon Recent Developments and Future Plans
2.10 Eisai Pharmaceuticals
2.10.1 Eisai Pharmaceuticals Details
2.10.2 Eisai Pharmaceuticals Major Business
2.10.3 Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Product and Solutions
2.10.4 Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Eisai Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Non-Hodgkin Lymphoma Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Non-Hodgkin Lymphoma Therapeutics Players Market Share
3.2.2 Top 10 Non-Hodgkin Lymphoma Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Non-Hodgkin Lymphoma Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Non-Hodgkin Lymphoma Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Non-Hodgkin Lymphoma Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Non-Hodgkin Lymphoma Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Non-Hodgkin Lymphoma Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Non-Hodgkin Lymphoma Therapeutics Revenue by Type (2016-2026)
6.2 North America Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2016-2026)
6.3 North America Non-Hodgkin Lymphoma Therapeutics Market Size by Country
6.3.1 North America Non-Hodgkin Lymphoma Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Non-Hodgkin Lymphoma Therapeutics Revenue by Type (2016-2026)
7.2 Europe Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2016-2026)
7.3 Europe Non-Hodgkin Lymphoma Therapeutics Market Size by Country
7.3.1 Europe Non-Hodgkin Lymphoma Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Market Size by Region
8.3.1 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue by Region (2016-2026)
8.3.2 China Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Non-Hodgkin Lymphoma Therapeutics Revenue by Type (2016-2026)
9.2 South America Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2016-2026)
9.3 South America Non-Hodgkin Lymphoma Therapeutics Market Size by Country
9.3.1 South America Non-Hodgkin Lymphoma Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Size by Country
10.3.1 Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Non-Hodgkin Lymphoma Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Non-Hodgkin Lymphoma Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Non-Hodgkin Lymphoma Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Non-Hodgkin Lymphoma Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. Bristol Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 7. Bristol Myers Squibb Major Business
Table 8. Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Product and Solutions
Table 9. Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Celgene Corporate Information, Head Office, and Major Competitors
Table 11. Celgene Major Business
Table 12. Celgene Non-Hodgkin Lymphoma Therapeutics Product and Solutions
Table 13. Celgene Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 15. Eli Lilly Major Business
Table 16. Eli Lilly Non-Hodgkin Lymphoma Therapeutics Product and Solutions
Table 17. Eli Lilly Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. F. Hoffman La-Roche Corporate Information, Head Office, and Major Competitors
Table 19. F. Hoffman La-Roche Major Business
Table 20. F. Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Product and Solutions
Table 21. F. Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 23. GlaxoSmithKline Major Business
Table 24. GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Product and Solutions
Table 25. GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Accredo Health Group Corporate Information, Head Office, and Major Competitors
Table 27. Accredo Health Group Major Business
Table 28. Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Product and Solutions
Table 29. Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Baxter International Corporate Information, Head Office, and Major Competitors
Table 31. Baxter International Major Business
Table 32. Baxter International Non-Hodgkin Lymphoma Therapeutics Product and Solutions
Table 33. Baxter International Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Bayer Corporate Information, Head Office, and Major Competitors
Table 35. Bayer Major Business
Table 36. Bayer Non-Hodgkin Lymphoma Therapeutics Product and Solutions
Table 37. Bayer Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Cephalon Corporate Information, Head Office, and Major Competitors
Table 39. Cephalon Major Business
Table 40. Cephalon Non-Hodgkin Lymphoma Therapeutics Product and Solutions
Table 41. Cephalon Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Eisai Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 43. Eisai Pharmaceuticals Major Business
Table 44. Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Product and Solutions
Table 45. Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 47. Global Non-Hodgkin Lymphoma Therapeutics Revenue Share by Players (2019-2021)
Table 48. Breakdown of Non-Hodgkin Lymphoma Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Non-Hodgkin Lymphoma Therapeutics Players Head Office, Products and Services Provided
Table 50. Non-Hodgkin Lymphoma Therapeutics Mergers & Acquisitions in the Past Five Years
Table 51. Non-Hodgkin Lymphoma Therapeutics New Entrants and Expansion Plans
Table 52. Global Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 53. Global Non-Hodgkin Lymphoma Therapeutics Revenue Share by Type (2016-2021)
Table 54. Global Non-Hodgkin Lymphoma Therapeutics Revenue Forecast by Type (2021-2026)
Table 55. Global Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2016-2021)
Table 56. Global Non-Hodgkin Lymphoma Therapeutics Revenue Forecast by Application (2021-2026)
Table 57. North America Non-Hodgkin Lymphoma Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Non-Hodgkin Lymphoma Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Non-Hodgkin Lymphoma Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Non-Hodgkin Lymphoma Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Non-Hodgkin Lymphoma Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Non-Hodgkin Lymphoma Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Non-Hodgkin Lymphoma Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Non-Hodgkin Lymphoma Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Non-Hodgkin Lymphoma Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Non-Hodgkin Lymphoma Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Non-Hodgkin Lymphoma Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Non-Hodgkin Lymphoma Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Non-Hodgkin Lymphoma Therapeutics Picture
Figure 2. Global Non-Hodgkin Lymphoma Therapeutics Revenue Market Share by Type in 2020
Figure 3. Chemotherapy
Figure 4. Targeted Therapy
Figure 5. Non-Hodgkin Lymphoma Therapeutics Revenue Market Share by Application in 2020
Figure 6. Clinical Research Picture
Figure 7. Treatment Picture
Figure 8. Global Non-Hodgkin Lymphoma Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 9. Global Non-Hodgkin Lymphoma Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 10. Global Non-Hodgkin Lymphoma Therapeutics Revenue Market Share by Region (2016-2026)
Figure 11. Global Non-Hodgkin Lymphoma Therapeutics Revenue Market Share by Region in 2020
Figure 12. North America Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 13. Europe Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. South America Non-Hodgkin Lymphoma Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Non-Hodgkin Lymphoma Therapeutics Market Drivers
Figure 17. Non-Hodgkin Lymphoma Therapeutics Market Restraints
Figure 18. Non-Hodgkin Lymphoma Therapeutics Market Trends
Figure 19. Bristol Myers Squibb Recent Developments and Future Plans
Figure 20. Celgene Recent Developments and Future Plans
Figure 21. Eli Lilly Recent Developments and Future Plans
Figure 22. F. Hoffman La-Roche Recent Developments and Future Plans
Figure 23. GlaxoSmithKline Recent Developments and Future Plans
Figure 24. Accredo Health Group Recent Developments and Future Plans
Figure 25. Baxter International Recent Developments and Future Plans
Figure 26. Bayer Recent Developments and Future Plans
Figure 27. Cephalon Recent Developments and Future Plans
Figure 28. Eisai Pharmaceuticals Recent Developments and Future Plans
Figure 30. Global Non-Hodgkin Lymphoma Therapeutics Revenue Share by Players in 2020
Figure 31. Non-Hodgkin Lymphoma Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 32. Global Top 3 Players Non-Hodgkin Lymphoma Therapeutics Revenue Market Share in 2020
Figure 33. Global Top 10 Players Non-Hodgkin Lymphoma Therapeutics Revenue Market Share in 2020
Figure 34. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 35. Global Non-Hodgkin Lymphoma Therapeutics Revenue Share by Type in 2020
Figure 36. Global Non-Hodgkin Lymphoma Therapeutics Market Share Forecast by Type (2021-2026)
Figure 37. Global Non-Hodgkin Lymphoma Therapeutics Revenue Share by Application in 2020
Figure 38. Global Non-Hodgkin Lymphoma Therapeutics Market Share Forecast by Application (2021-2026)
Figure 39. North America Non-Hodgkin Lymphoma Therapeutics Sales Market Share by Type (2016-2026)
Figure 40. North America Non-Hodgkin Lymphoma Therapeutics Sales Market Share by Application (2016-2026)
Figure 41. North America Non-Hodgkin Lymphoma Therapeutics Revenue Market Share by Country (2016-2026)
Figure 42. United States Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Canada Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Mexico Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Europe Non-Hodgkin Lymphoma Therapeutics Sales Market Share by Type (2016-2026)
Figure 46. Europe Non-Hodgkin Lymphoma Therapeutics Sales Market Share by Application (2016-2026)
Figure 47. Europe Non-Hodgkin Lymphoma Therapeutics Revenue Market Share by Country (2016-2026)
Figure 48. Germany Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. France Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. United Kingdom Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Russia Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Italy Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Sales Market Share by Type (2016-2026)
Figure 54. Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Sales Market Share by Application (2016-2026)
Figure 55. Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue Market Share by Region (2016-2026)
Figure 56. China Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Japan Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. South Korea Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. India Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Southeast Asia Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Australia Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South America Non-Hodgkin Lymphoma Therapeutics Sales Market Share by Type (2016-2026)
Figure 63. South America Non-Hodgkin Lymphoma Therapeutics Sales Market Share by Application (2016-2026)
Figure 64. South America Non-Hodgkin Lymphoma Therapeutics Revenue Market Share by Country (2016-2026)
Figure 65. Brazil Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Argentina Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Sales Market Share by Type (2016-2026)
Figure 68. Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Sales Market Share by Application (2016-2026)
Figure 69. Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Revenue Market Share by Country (2016-2026)
Figure 70. Turkey Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Saudi Arabia Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. UAE Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Methodology
Figure 74. Research Process and Data Source
世界のホジキンリンパ腫治療市場規模・現状・予測（2021年-2027年） Hodgkin's Lymphoma (HL) is defined as the cancer of the lymph tissue, which is part of our immune system. The exact etiology of HL is unknown. However, the risk of developing the condition is increased if a person suffers from a medical condition that weakens the immune system. In HL, cells in the l…- 世界の非ホジキンリンパ腫治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Non-Hodgkin Lymphoma Therapeutics Market The global Non-Hodgkin Lymphoma Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high da…
- 世界のホジキンリンパ腫治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Hodgkin Lymphoma Treatment Market The global Hodgkin Lymphoma Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, …
- 世界の非ホジキンリンパ腫（NHL）市場規模・現状・予測（2021年-2027年） Non-Hodgkin Lymphoma is the most common lymphoma which affects large number of people. It begins in lymphocytes present in lymph nodes of body parts such as neck or chest or under the arms. It widely spreads to the other lymph nodes and to other organs such as bone marrow, lungs, or liver. Market An…
- 世界のリンパ腫治療市場規模・現状・予測（2021年-2027年） Lymphoma is cancer that begins in infection-fighting cells of the immune system, called lymphocytes. These cells are in the lymph nodes, spleen, thymus, bone marrow, and other parts of the body. When you have lymphoma, lymphocytes change and grow out of control Market Analysis and Insights: Global L…